- Push-out Score determined
- After around 13 years in the position
- Praise for Anderson
- Marc Stapley taking over
- Anderson will remain as executive chairman at Veracyte
- Anderson spoke at length and said 148 words
(exechange) — South San Francisco, California, May 10, 2021 — Bonnie Anderson, chief executive of Veracyte, leaves her position. As announced by Veracyte Inc. in a news release and in a regulatory filing published on Monday, May 10, 2021, Bonnie H. Anderson leaves her post as chief executive officer at the genomic diagnostics company after around 13 years in the role, effective June 1, 2021.
Bonnie Anderson’s duties as CEO will be taken over by Marc Stapley, most recently chairman and chief executive officer at Helix, Inc.
The fact that Bonnie Anderson’s successor is brought in from outside suggests that the board may seek to stimulate change with fresh ideas and new initiatives.
“Now is the perfect time”
Bonnie Anderson’s departure from the CEO post is explained as follows. Anderson said: “Now is the perfect time to implement Veracyte’s CEO succession plan.”
Anderson will remain as executive chairman at Veracyte
“Ms. Anderson will move into an active executive chairman role, serving as a trusted advisor to Mr. Stapley, for the next few years to ensure a smooth transition, and will continue to serve on the board,” Veracyte said.
Veracyte said: “Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced its executive leadership succession plan, with industry veteran Marc Stapley to succeed Veracyte cofounder, Bonnie Anderson, as chief executive officer.”
Veracyte further said: “On May 10, 2021, the Company announced that the Board of Directors of the Company (the “Board”) appointed Marc Stapley as the Chief Executive Officer of the Company, effective as of June 1, 2021 (the “Transition Date”), and as a Class II director of the Board, effective following the Company’s annual meeting of stockholders to be held on June 7, 2021. Effective as of the Transition Date, Bonnie H. Anderson, the Company’s Chief Executive Officer and chairman of the Board, will resign from her position as Chief Executive Officer and be appointed as the Company’s Executive Chair.”
Share price increase since May 2020
The announcement follows an increase in Veracyte Inc.’s share price of 69% since May 2020.
In the position of CEO since 2008
Bonnie Anderson became CEO of the Company in 2008.
The CEO succession is effective June 1, 2021, with Stapley joining the board after Veracyte’s 2021 Annual Meeting of Stockholders on June 7, 2021.
Bonnie H. Anderson has served as the Company’s co-founder, Chief Executive Officer and as a member of the Company’s board of directors since February 2008 and as the Chairman of the Company’s board of directors since December 2016.
From August 2013 to February 2017, she also served as the Company’s President.
Prior to joining the Company, Anderson was an independent strategic consultant from April 2006 to January 2008, including as a strategic consultant for the Company from July 2007 to January 2008.
Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006.
Anderson currently serves as a member of the board of directors of Bruker Corporation and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences.
Anderson previously served as a member of the board of directors of Castle Biosciences, Inc. from June 2015 to August 2020.
Anderson holds a B.S. in Medical Technology from Indiana University of Pennsylvania.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Bonnie Anderson’s move on a scale of 0 to 10.
exechange reached out to Veracyte and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 20.2021 ($).